Actively Recruiting

Age: 18Years +
All Genders
ID07262255

WATCHMAN FLX Pro European Registry for Left Atrial Appendage Closure in Non-valvular Atrial Fibrillation

Led by Boston Scientific Corporation · Updated on 2026-05-26

1000

Participants Needed

13

Research Sites

56 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are collecting real-world clinical data on patients undergoing left atrial appendage closure (LAAC) with the WATCHMAN FLX Pro device. This registry focuses on adults with non-valvular atrial fibrillation who are eligible or have contraindications for anticoagulation therapy. A subgroup of about 300 patients will have the procedure performed using the VersaCross Connect LAAC Access Solution to aid catheter access. Participants undergo the LAAC procedure with the WATCHMAN FLX Pro device, which aims to prevent blood clots from forming in the heart's left atrial appendage and reduce bleeding risks. In the subregistry, the VersaCross Connect LAAC Access Solution is used during the procedure to facilitate catheter entry via transseptal puncture. The study observes patients receiving these devices in routine clinical practice. Throughout the study, researchers monitor safety events related to both the WATCHMAN FLX Pro device and the VersaCross Connect Access Solution from the procedure until 7 days after or hospital discharge. They also track successful use of the Access Solution by confirming completion of the transseptal puncture. Participants must provide informed consent and attend follow-up visits, with the study planned to conclude in September 2028.

CONDITIONS

Brief Title

WATCHMAN FLX Pro European Registry

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Subject is attempted to be treated with the WATCHMAN FLX Pro LAAC device.
  • Subject has non-valvular atrial fibrillation without moderate or greater mitral stenosis or a mechanical heart valve and is clinically indicated for the WATCHMAN FLX Pro LAAC device.
  • Subject or legal representative is willing and able to provide informed consent.
  • Subject is able and willing to return for required follow-up visits and examinations.
  • Subject is aged 18 years or older or of legal age to give informed consent according to state and national law.
Not Eligible

You will not qualify if you...

  • Subject has a documented life expectancy of less than 12 months.
  • Subject is currently enrolled in another investigational study or registry except for mandatory governmental or purely observational registries.
  • Intracardiac thrombus is present.
  • An atrial septal defect repair or closure device or patent foramen ovale repair or closure device is present.
  • The left atrial appendage anatomy cannot accommodate a closure device.
  • Subject has known hypersensitivity or contraindications according to the device Instructions for Use.
  • Subject is of childbearing potential and is or plans to become pregnant during the study.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Implementation

Duration - Procedure day and up to 7 days following the procedure or until hospital discharge, whichever is later

Participants undergo the left atrial appendage closure procedure using the WATCHMAN FLX Pro device and VersaCross Connect™ LAAC Access Solution.

1 procedure visit and follow-up visits within 7 days post-procedure

Long-term Monitoring

Duration - Up to approximately 5 years until study completion

Participants are observed to collect real world clinical data following the left atrial appendage closure procedure.

Follow-up visits as per clinical routine

Trial Site Locations

Total: 13 locations

1

Aarhus University Hospital

Aarhus, Denmark, 8200

Actively Recruiting

2

Rigshospitalet Copenhagen

Copenhagen, Denmark, 2100

Actively Recruiting

3

Kath Krankenhaus St Johann Nepomuk

Erfurt, Germany, 99097

Actively Recruiting

4

Asklepios Klinik Saint Georg

Hamburg, Germany, 20099

Actively Recruiting

5

Asklepios Klinik Nord Heidberg

Hamburg, Germany, 22417

Actively Recruiting

6

Asklepios Klinik Altona

Hamburg, Germany, 22763

Actively Recruiting

7

Centro Cardiologico Monzino

Milan, Italy, 20138

Actively Recruiting

8

Hospital de Leon

León, Spain, 24071

Actively Recruiting

9

Clinica Universidad de Navarra

Pamplona, Spain, 31008

Actively Recruiting

10

Complejo Hospitalario Universitario de Pontevedra

Pontevedra, Spain, 36001

Actively Recruiting

11

Hospital Clinico Salamanca

Salamanca, Spain, 37007

Actively Recruiting

12

University Hospital Basel

Basel, Switzerland, 4031

Actively Recruiting

13

INSELSPITAL - Universitätsspital Bern

Bern, Switzerland, CH-3010

Actively Recruiting

Loading map...

Research Team

T

Thomas Näschen, PhD

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Similar Trials

Agilis Radiofrequency Transseptal System Early Feasibility S...

Cardiac Arrythmias

Actively Recruiting

3 locations

Austrian Left Atrial Appendage Closure Registry

Atrial Fibrillation

Actively Recruiting

1 location

CLOT-LESS - CLOsure Tailored: LEss Antithrombotic Strategy A...

Atrial Fibrillation

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here